PHOTO
Amman - Hikma Pharmaceuticals PLC (HikmaGroup) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P) the multinational pharmaceutical company, today announced an exclusive licensing and distribution agreement with Chiesi Farmaceutici, a research-focused international pharmaceutical group (Chiesi Group), headquartered in Italy.
The agreement provides Hikma with exclusive rights to commercialise 11 of Chiesi’s leading products in Egypt, including currently marketed and pipeline products. This builds on Hikma’s existing partnership with Cheisi in Morocco and adds a range of innovative products to its Egyptian portfolio, including Foster®, Foster Nexthaler®, Trimbow® and Curosurf®.
Mazen Darwazah, Hikma Executive Vice Chairman and President of MENA, said: “We are very pleased to be partnering with Chiesi to commercialise a range of specialty products, primarily in respiratory and neonatal therapeutic areas, in Egypt. This supports our strategy of working with global partners to strengthen our portfolio in growing therapeutic categories. In particular, this agreement enables us to meet the needs of a growing number of patients suffering from asthma and COPD in Egypt, and improve their access to high quality medicines.”
Ugo Di Francesco, CEO of Chiesi Group, commented: “We are really proud to have strengthened our strategic partnership with Hikma. This will allow us to increase the availability of our main therapeutic solutions in the respiratory and neonatology fields to Egyptian patients. The agreement highlights our continued progress against Chiesi Group’s main mission; addressing population health needs around the world.”
- Ends-
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.
About Chiesi Group
Based in Parma, Italy, Chiesi Farmaceutici is an international research-oriented group with over 80 years of experience in the pharmaceutical sector, operating in 28 countries. The Group conducts research, develops and markets innovative drugs for respiratory treatment, Special Care medicine and rare diseases. The Group’s Research and Development Centre is based in Parma and integrates its work with that of 6 other important R&D groups in France, the USA, the UK and Sweden to promote its own pre-clinical, clinical and registration programmes. The Chiesi Group is a certified B Corp and employs around 5,700 people. For further information, please visit www.chiesi.com.
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal
EVP, Strategic Planning and Global Affairs
+44 (0)20 7399 2760/ +44 7776 477050
uk-investors@hikma.uk.com
Dana Alhusseini
Communication Manager
+962 6 580 2900
Dalhusseini@hikma.com
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
